MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
11 mars 2025 16h05 HE
|
MaxCyte, Inc.
ROCKVILLE, MD, March 11, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06 nov. 2024 16h05 HE
|
MaxCyte, Inc.
ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development,...
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
06 août 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, August 6, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
07 mai 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused...
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
12 mars 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD, March 12, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
04 mars 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company...
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
08 janv. 2024 16h05 HE
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD, January 8, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
08 nov. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD, November 8, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...
MaxCyte to Participate in Two Upcoming Investor Conferences
06 nov. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD, November 6, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling...
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
04 oct. 2023 16h05 HE
|
MaxCyte, Inc.
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD, October 4, 2023 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,...